Immunotherapy in Locally Advanced Head and Neck Cancer: Evidence, Impact, and Integration Authors: Hisham Mehanna, FMedSci, PhD, BMedSc (hons), MB ChB (hons), FRCS, FRCS (ORL-HNS); Robert Haddad, MD

https://www.medscape.org/viewarticle/immunotherapy-locally-advanced-head-and-neck-cancer-evidence-2026a1000khq?page=1&src=mkmcmr_driv_stan_mscpedu_261109-OUS-HONC-immunotherapy-locally-advanced-head-and-neck-cancer-evidence-2026a1000khq-cta&uac=148436CN

FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy (+++)

https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-malignancy-linked-zolgensma-gene-therapy?utm_medium=email&utm_source=govdelivery 2026 Safety and Availability Communications https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/2026-safety-and-availability-communications OTP Guidance Webinar: Potency Assurance for Cellular and Gene Therapy Products December 10, 2026 Office of Therapeutic Products (OTP) https://www.fda.gov/vaccines-blood-biologics/office-therapeutic-products-otp-events-meetings-and-workshops/otp-guidance-webinar-potency-assurance-cellular-and-gene-therapy-products-12102026?utm_medium=email&utm_source=govdelivery

Translating Molecular Insights Into Practice for HR-Positive/HER2-Negative Metastatic Breast Cancer Authors: Hope Rugo, MD; Peter A. Fasching, MD

https://www.medscape.org/viewarticle/translating-molecular-insights-practice-hr-positive-her2-2026a1000y0g?page=1&src=mkm_driv_cust_mscpedu_261105-12384304&uac=148436CN

Refining Adjuvant Therapy in HR-Positive/HER2-Negative Early Breast Cancer: Personalizing Care in the CDK4/6 Inhibitor Era Authors: Nadia Harbeck, MD, PhD; Frédérique Penault-Llorca, MD; Giampaolo Bianchini, MD; Henry Cain, MBChB, FRCS, MD; Janice Walshe, MB BCh, BAO, MRCPI

https://www.medscape.org/viewarticle/refining-adjuvant-therapy-hr-positive-her2-negative-early-2026a1000ysl?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_261105-OUS-HONC-refining-adjuvant-therapy-hr-positive-her2-negative-early-2026a1000ysl-cta

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2026

https://www.medscape.com/c25/p14/american-association-neuromuscular-electrodiagnostic-2026a1000qkl?ecd=wnl_conf_neuro_AANEM_SPON_261105_mscpedit_etid8871049&uac=148436CN&impID=8871049

Advancing Care in HER2-Mutated NSCLC: Evidence, Diagnostics, and Future Directions Authors: Balazs Halmos, MD, MS

https://www.medscape.org/viewarticle/advancing-care-her2-mutated-nsclc-evidence-diagnostics-and-2026a1000d6g?page=1&src=mkmcmr_driv_stan_mscpedu_261105-OUS-HONC-advancing-care-her2-mutated-nsclc-evidence-diagnostics-and-2026a1000d6g-cta&uac=148436CN

Medical Device Cybersecurity

https://www.fda.gov/medical-devices/medical-device-cybersecurity?utm_medium=email&utm_source=govdelivery FDA Enhances Medical Device Cybersecurity Web Content The U.S. Food and Drug Administration has updated its medical device cybersecurity webpages to make key information and resources easier to find and use. What’s new: Refreshed main page within the Medical Devices section, with improved visibility and usability. Updated Guidance and FAQs with current information. Two new webpages with resources on securing medical devices and information about cybersecurity collaborations. Explore the updated content to find resources and information to help address cybersecurity considerations for medical devices.